Literature DB >> 20506394

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor.

Bernardo Nuche-Berenguer1, Sergio Portal-Núñez, Paola Moreno, Nieves González, Alicia Acitores, Ana López-Herradón, Pedro Esbrit, Isabel Valverde, María L Villanueva-Peñacarrillo.   

Abstract

Glucagon-like peptide 1 (GLP-1) controls glucose metabolism in extrapancreatic tissues through receptors other than the pancreatic cAMP-linked GLP-1 receptor; also, GLP-1 induces an insulin- and PTH-independent bone anabolic action in insulin-resistant and type-2 diabetic rats. Here we searched for the presence and characteristics of GLP-1 receptors in osteoblastic MC3T3-E1 cells. [(125)I]-GLP-1 specific binding to MC3T3-E1 cells was time- and temperature-dependent, reaching maximal value at 30 min at 25 degrees C; in these conditions, [(125)I]-GLP-1 binding was dissociable, and displaced by GLP-1, partially by GLP-2, but not by exendin-4 (Ex-4), exendin-9 (Ex-9), glucagon or insulin; Scatchard analysis of the unlabeled GLP-1 data showed high and low affinity binding sites; cross-linking of GLP-1 binding revealed an estimated 70 kDa band, almost undetectable in the presence of 10(-6) M GLP-1. GLP-1, Ex-9, insulin or glucagon failed to modify cellular cAMP content, while GLP-2 and Ex-4 increased it. However, GLP-1 induced an immediate hydrolysis of glycosylphosphatidylinositols (GPIs) generating short-lived inositolphosphoglycans (IPGs), and an increase in phosphatidylinositol-3 kinase (PI3K) and mitogen activated protein kinase (MAPK) activities; Ex-4 also affected GPIs, but its action was delayed with respect to that of GLP-1. This incretin was found to decrease Runx2 but increased osteocalcin gene expression, without affecting that of osteoprotegerin or the canonical Wnt pathway activity in MC3T3-E1 cells which do not express the pancreatic GLP-1 receptor. Our data demonstrate for the first time that GLP-1 can directly and functionally interact with osteoblastic cells, possibly through a GPI/IPG-coupled receptor. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20506394     DOI: 10.1002/jcp.22243

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  46 in total

1.  Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance.

Authors:  Sophia Ouhilal; Patricia Vuguin; Lingguang Cui; Xiu-Quan Du; Richard W Gelling; Sandra E Reznik; Robert Russell; Albert F Parlow; Clara Karpovsky; Nanette Santoro; Maureen J Charron
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-13       Impact factor: 4.310

2.  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

Authors:  Emily Jane Gallagher; Hui Sun; Caroline Kornhauser; Aviva Tobin-Hess; Sol Epstein; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes Metab Res Rev       Date:  2014-03       Impact factor: 4.876

3.  Changes in Bone Mineral Density in Patients with Type 2 Diabetes After Different Bariatric Surgery Procedures and the Role of Gastrointestinal Hormones.

Authors:  Fernando Guerrero-Pérez; Anna Casajoana; Carmen Gómez-Vaquero; Nuria Virgili; Rafael López-Urdiales; Laura Hernández-Montoliu; Jordi Pujol-Gebelli; Javier Osorio; Carolina Alves; Manuel Perez-Maraver; Silvia Pellitero; Anna Vidal-Alabró; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

Review 4.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

5.  Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength.

Authors:  A Mieczkowska; S Mansur; B Bouvard; P R Flatt; B Thorens; N Irwin; D Chappard; G Mabilleau
Journal:  Osteoporos Int       Date:  2014-08-16       Impact factor: 4.507

Review 6.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

7.  The bone-preserving effects of exendin-4 in ovariectomized rats.

Authors:  Han-Xiao Sun; Nan Lu; Dong-Mei Liu; Lin Zhao; Li-Hao Sun; Hong-Yan Zhao; Jian-Min Liu; Bei Tao
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

8.  [Diabetes and osteoporosis: pathophysiological interactions and clinical importance for geriatric patients].

Authors:  M Lechleitner; K Pils; R Roller-Wirnsberger; E Beubler; R Gasser; P Mrak; F Hoppichler; P Pietschmann
Journal:  Z Gerontol Geriatr       Date:  2013-07       Impact factor: 1.281

Review 9.  Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Authors:  Guojing Luo; Hong Liu; Hongyun Lu
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

10.  The deleterious effect of bariatric surgery on cortical and trabecular bone density in the femurs of non-obese, type 2 diabetic Goto-Kakizaki rats.

Authors:  José Luis Pérez-Castrillón; José Antonio Riancho; Daniel de Luis; José Ramón Caeiro; David Guede; Manuel González-Sagrado; Marta Ruiz-Mambrilla; María Domingo-Andrés; Rosa Conde; David Primo-Martín
Journal:  Obes Surg       Date:  2012-11       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.